Search results

Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated leadership of the PI3K space and has a deep pipeline of novel differentiated assets across various stages of development.

GlycoEra is developing biologics to selectively degrade autoimmune disease causing circulating proteins rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies.

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.

Pharma-Consulting ENABLE GmbH provides support to biopharmaceutical companies (small & large) in product development and manufacturing covering early to late stage clinical and commercial operations. Pharma-Consulting ENABLE is active worldwide and has been created by Alain Pralong in 2008.

MUVON is a Swiss, clinical stage biotech company with the goal of revolutionizing the treatment of diseases caused by muscle damage or degradation through the use of the patients' own cells. Our initial area of focus is the treatment of stress urinary incontinence in women (PhII completed).

Spin-off from EPFL developing precision gene therapies for Amyotrophic Lateral Sclerosis (ALS). ALS pathogenic mechanisms support that non-neuronal cells play a key role in this disease, through reshaping neuronal synaptic connections.

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical tria

A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indications in IBD, dysbiosis induced by antibiotic treatments and unhealthy diet, and as enhancer in cancer immunotherapy.

Centenara is an integrated biotechnology platform company that develops and improves therapies and technologies to promote healthy aging and prolong lifespan. We provide start-up coaching and funding to entrepreneurial scientists to co-create therapies that benefit our aging population.

Gut-restricted metabolic therapies. Validated platform with 3 preclinical proof-of-concepts. Established as a private company (AG) in Basel in 2019. Secured a partnership with Nestlé Health Science for one asset. Raised CHF 10M in equity and non-dilutive funding. Raising Series A.

Ceidos is a Swiss biotech company developing the C-Netics, an innovative device for automated cell culture monitoring. Their mission is to optimize bioproduction processes for modern treatments through automation and innovative technologies.

GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform and pipeline of molecules targeting brain glial cells to restore brain metabolism deficits in neurological diseases linked to brain metabolism dysfunction.

Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications. We are rapidly advancing our pipeline of antibodies and antibody-drug conjugates through clinical development.

DiNAQOR has developed a proprietary technology platform and manufacturing capabilities designed to overcome the challenges and limitations of early-stage gene therapy development.

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases.

SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development platform targeting neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).

Synendos is a clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and neurological disorders through the modulation of a new drug target in the endocannabinoid system enabling restoration of the natural functioning of the brain.

Sferalp is specialized in the formulation of Self Emulsifying Oils (SEFO) containing extracts or API. SEFO maximize gastro-intestinal absorption. We have developed a SEFO based on natural food components (Patent pending). We provide development in the field of electro- and conventional spray drying.

At Nagi Bioscience we create cutting-edge biological testing solutions that empower scientists with actionable data to fuel discoveries in a faster, efficient, and ethical way. Our Organism-on-Chip platform, SydLab™ One, enables automated in vivo testing at the in vitro scale in high-throughput.

MesenFlow Technologies has developed a service platform to meet the demands of modern drug development. It has been designed to accelerate the development process and provide solutions to common problems associated with species cross-reactivity, animal testing and understanding human disease.

Cerdia, headquartered in Basel, is a pioneer in cellulose acetate tow since 1912 and a global quality and innovation leader of filter tow for cigarette manufacture. We are developing innovative applications and processes that will define Cellulose Acetate as a sustainable raw material in the future.

We focus our efforts on supporting injection devices, medical devices, IVD, combination product developments and compliance projects for our pharmaceutical and biotech clients, who either lack resources familiar with medical device development or wish to complement their existing resources.

Orion Biotechnology is a Swiss/Canadian clinical stage company. Orion is the only company with a novel approach to drug peptide and protein GPCRs. Our platform offers one of the fastest drug discovery solutions in industry to target peptidergic GPCRs. Orion has a strong and diverse pipeline.

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.

Being a Swiss technology innovation center we develop and transfer advanced technologies to the industrial sector. We are a non-profit orientated, public-private organization and collaborate with scientific and research institutes, and industrial partners. CSEM is active all over Switzerland.

Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.

Artidis® is a pioneering clinical stage health technology company that aims to set the gold standard in tissue analysis and therapy optimization. Artidis focuses its efforts on solid tumors to enhance responses to chemo, immuno, and cell therapies, driving precision in cancer care.

abc biopply AG is pioneering NAM technologies and organoid CRO services that boost in vitro studies for drug discovery and development to IND relevance using its proprietary 3D CoSeedis Multi-Organoid in chip Technology™ on clinically relevant disease models (oncology, neurology, obesity and others).

SunRegen is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases.

TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies.

Selective mode antimicrobial resistance therapeutics Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance. Focus on high revenue segment - patients in hospitals.

There is a new kit on the block. Swiss start-up NEMIS Technologies AG specialises in the development of simple, safe, and on-site pathogen testing solutions. Its detection test for Listeria monocytogenes is already commercially available in Switzerland, France, and Spain.

IPS Biopharma AG is tackling one of the biggest challenges in cancer treatment: recurrence. Our phase 2 asset, IP‑001, can activate specific anti-tumor immunity following in situ tumor destruction, turning standard focal interventions into a potential catalyst for durable anti-cancer immunity.

We provide our clients, however complex their challenges may be, with effective and high quality solutions throughout the life cycle of their products and the evolution of their company.

HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer.

Swiss-based Life Sciences consultancy and part of the athagoras Group. We enable European market access for pharma & biotech, combining strategy, evidence generation and HTA expertise, from valuation and trial design to reimbursement, JSC, JCA and pricing negotiations.

iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families.

Experts in Life Science products Witec AG is your innovative Swiss Partner for Life Science Products since 1988. We deliver cutting-edge instruments and consumables backed by exceptional, agile service and an unwavering commitment to accelerating your research.

Xenometrix delivers innovative, reliable bioassays for the safety assessment of test compounds in mutagenesis, genotoxicity, endocrine activity and explants for absorption tests (IVPT), combining Swiss quality, scientific expertise, and customer-focused support for global research, regulatory needs.

Wyss Zurich is a joint accelerator of ETH & University of Zurich. Our mission is to drive the clinical translation of outstanding scientific discoveries into new therapies for patients and innovations in the fields of regenerative medicine and robotics, and hybrid technologies in these fields.

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.

TOLREMO engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies.

At UCB, we are inspired by patients and driven by science. Our strategy: to offer value to people suffering from severe diseases in neurology and immunology. In Switzerland, UCB invested around 800 million CHF in his plant for industrial equipment on the cutting edge of technology and innovation.

Synple Chem was founded to develop new easy to use automated laboratory equipment for chemistry research labs.

Tepthera is a spin off from the ETH Zurich focusing on product development in the field of cancer immunotherapy, autoimmune- and infectious diseases.

SpacePharma provides researcher, institutes and commercial companies an easy and affordable access to the microgravity environment. Our novel technology enables researchers to perform complex chemical and biological experiments with our proven cutting-edge remote-control technology and labs in space.

SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 750 institutions in over 70 countries.  Our network advances data-driven medicine to improve health outcomes and economics worldwide.

Securecell is an innovator for both the biotech and medtech space. Developing use-case applications for automated bioprocessing and smart pharmacoligical facilities, as well as the transformative applications of digital technologies to help hospitals and life scientists solve next-world problems.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.

Regen Lab is a global leader in products for autologous regenerative medicine based on freshly prepared platelet rich plasma from the patient’s own blood, used either alone or combination with hyaluronic acid or other fresh autologous cells from the patient’s fat or bone marrow.

As Swiss branch of Promega Corp, Promega AG offers local scientific expertise for 4000+ products covering genomics, proteomics and cell analysis. Promega is a global leader in providing innovative solutions for drug discovery, basic research, human identification, diagnostics and food/water testing.

We develop complex dosage forms enabling early market entry generic drugs and innovative supergeneric products. We deal with licensing-out to leading Pharma partners worldwide for market access.

Oculox Technologies is a medical device company focused on the application of state-of-the art micro and laser technology in the field of medical diagnostics and therapy.

OMNI Life Science GmbH is located in Basel, Switzerland. We are your local partner for solutions in cell-based assays and are dedicated to provide innovative solutions for research in life science.

We specialize in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind.

Oculis is a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Headquartered in Switzerland, Oculis is led by an experienced management team and supported by leading international healthcare investors.

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Novaremed AG, a privately held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment options as an alternative to opioids. HQ Basel (Switzerland); subsidiaries Novaremed Ltd (Israel) & Metys Pharmaceuticals (CH).

Novigenix AI is a TechBio that powers precision medicine through its proprietary AI-enabled liquid biopsy mRNA platform, LITOSeek, to map immune-response dynamics across disease onset and progression—turning biology into actionable insights for therapy development.

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Novassay is a biotech active in the area of Ion Channel therapeutics with focus in neuropathic pain and Oncology. We have a portfolio of assets currently in development (approaching IND stage) and interested in partnering and R&D collaborations.

Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018. We now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

NBE-Therapeutics engages in the development of “next-generation”, antibody drug conjugates (ADCs) with the objective to develop first-in-class ADC product candidates until clinical proof-of-concept in patients. NBE Therapeutics is part of the Boehringer-Ingelheim group.

Memo Therapeutics AG develops therapeutic antibodies for viral infections and cancer. Lead asset potravitug targets BKV in kidney transplant recipients; Phase II SAFE KIDNEY data, presented in Nov 2025, support a planned Phase III start in 2026. MTx is also building an oncology discovery pipeline.

MetrioPharm AG, a clinical stage biopharmaceutical development company based in Zurich with a subsidiary in Berlin, Germany, has developed a platform of small molecule drug candidates (oral and i.v.) which targets the modulation of immune cell metabolism without suppressing the immune system.

Microsphere (MS) is a CDMO focused on new developments, cGMP manufacturing, R&D, analytical and regulatory support. MS is able to address complex challenges, including formulations for poorly water-soluble drugs, considering the extensive expertise in Spray Drying and Capsule Filling.

LubioScience is the biggest lifescience reagents & services platform in Switzerland. Representing some of the world’s most recognized brands, we provide over 5 million products from more than 120 suppliers and pride ourselves in working with most Swiss biotech companies & start-ups.

Lunaphore has developed an innovative device for cancer tissue diagnostics. Its award-winning technology based on microfluidics aims to achieve faster & more precise results than current techniques. It was founded in 2004 with the vision of bringing –omics like approaches to tissue diagnostics. Lunaphor

Life Technologies Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community.

Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile populations, e.g. children, cancer patients and the elderly, who may be already on multiple medications.

LimmaTech Biologics AG is a Swiss clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to protect from the increasing threat of global microbial infections due to emerging antimicrobial resistance (AMR) and sexually transmitted diseases.

Kinematica is a mechanical engineering company from Lucerne. We have our expertise in the field of homogenization and dispersion equipment form lab to production scale. We focus on close collaboration with our customer to built and scale equipment on request - for homogenization perfected.

Laves-Arzneimittel GmbH has focused on the exploration and development of preparations based on the probiotic Escherichia coli strain Laves discovered in 1931 by Dr. Wolfgang Laves.

InterAx is a drug discovery firm spun out of ETHZ. Its Deep Signal platform combines AI with mechanistic cell signaling models to predict how drugs behave inside cells — designing medicines with better efficacy and fewer side effects. Pipeline spans metabolism and oncology, with pharma partnerships.

InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding healthy and diseased human physiology in vitro.

Based on the liposomal technology platform, InnoMedica has built a diversified pipeline with lead compounds in oncology and neurodegenerative diseases. Clinical trials for the treatment of breast cancer as well as Parkinson's disease are conducted in Swiss hospitals.

IBR Inc. is a GxP-compliant CRO offering advanced bioanalytical services for pre-clinical and clinical development of antibodies, biologics, biosimilars, antibody-drug conjugates and vaccines. The services include bioanalytics for product release under GMP.

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing novel human immunomodulatory proteins for cancer with a specific role in innate immunity.

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology.

Calliditas is a commercial-stage biopharmaceutical company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2021, Calliditas acquired Genkyotex, a French‑ and Swiss‑based company specializing in NOX therapies.

Our R&D center for biologics in Switzerland has end-to-end capabilities to discover Novel Biological Entities (NBEs) and develop them from inception through to pre-clinical & clinical studies. It is also fully equipped to manufacture clinical trial-size batch materials.

GMT Fine Chemicals SA is a Swiss company founded in 1998 based in Couvet (Neuchâtel). The company has been designed to allow the chemical synthesis of Active Pharmaceutical Ingredients (API) under conditions guaranteeing the quality of the products (GMP). Products are sold world-wide (EU, USA, JPN).

EspeRare is an ethical non-profit biotech. It combines pharmaceutical know-how and philanthropic and public investments to bring to life treatments that have been abandoned by the pharmaceutical industry. EspeRare represents an affordable alternative to the high cost innovation of medicines.

evitria specializes in CHO-based transient expression of recombinant proteins, with a focus on antibodies—including bispecific, Fc-silenced, and afucosylated formats. With over 100,000 transfections, we are a trusted partner for biotech and pharma worldwide.

EffRx Pharmaceuticals SA is a commercial-stage pharmaceutical company, based in Switzerland, that develops and commercializes prescription medications for specialty indications. The primary focus is on therapeutics for men and women with musculoskeletal, genitourinary and rare diseases. Abiogen Pharma acquire

CSL (ASX:CSL; USOTC:CSLLY) – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – is a global biotechnology leader that develops and delivers innovative lifesaving medicines, protects public health and helps people with life-threatening medical conditions live full lives.

Curatis acquires, licences, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and speciality diseases in Switzerland. We have a promising pipeline of novel speciality care and orphan drugs for neurological disorders.

DAMIAN Pharma is a privately-held pharmaceutical company incorporated in Switzerland, with access to one of the largest networks of life science companies and business experts. Led by an experienced team of executives, DAMIAN focuses on creating value that benefits patients and shareholders.

CRB is a leading design, construction and consulting firm serving life sciences companies globally since 1984. From small studies to execution of complex projects, we have the expertise to deliver solutions to our clients in the local pharmaceutical and biotechnology market.

We develop ADCs and radioligands, leveraging our conjugation platform. We create new treatments offering hope to patients that suffer from aggressive cancer with poor prognosis.

Celonic is a “Pure Play” Biologics CDMO with a focus on CHO-based expression systems. Celonic is a pioneer in using next generation bioprocessing technologies and has a state-of-the-art Biologics Development Center in Switzerland, with clinical and commercial GMP manufacturing facilities in Germany.

With over 40 years in the pharmaceutical industry, Cerbios is a privately held company headquartered in Barbengo‑Lugano, Switzerland, specialising in the development and manufacture of both chemical and biological APIs for its partners worldwide.

BÜHLMANN designs, develops, manufactures and sells worldwide innovative medical diagnostic products and kits (IVD or RUO) in inflammation, cellular allergy, neuroimmunology, clinical chemistry, chronobiology and others.

Bromatech has been engaged for more than 25 years in the study and development of targeted food supplements based on specific strains of lactic acid bacteria, antioxidants and essential fatty acids which are able to interact with the precious heritage of the human microbiota.

Catalent is the global leader in enabling pharma, cell & gene therapy and biopharma partners to optimize product development, launch, and full life-cycle supply for patients around the world. Catalent helps accelerate over 1,000 partner programs every year for partners of all sizes.

Securing life sciences supply chains. Complex chemicals, peptides and key biologics: products, services and innovation. Biosynth is a supplier of critical materials with chemicals on the milligram to ton scale, with peptides at mg to multikilogram scale. ISO 9001 and GMP facilities.

At Biogen, we develop, market and manufacture therapies for people living with serious neurological, autoimmune and rare diseases.

BioArk drives innovation and business growth from early stages to commercialization. With two technology parks in Valais and over 10,000 jobs, our ecosystem offers cutting-edge facilities, expert coaching, funding support, and a strong industrial and scientific network.

We at Bioengineering AG design and build customized equipment to improve bioproduction efficiency in biotech, novel food, and biopharma plants. Our engineering teams develop reliable bioreactors and fermenters, from lab scale to production, for clients worldwide. Trusted for over 50 years. In 2025 Bioengineer

Bio-Rad Laboratories continues to play a leading role in the advancement of scientific discovery by offering a broad range of innovative tools and services to the life science research and clinical diagnostics markets.

At BD, we are committed to sustainable healthcare. We are inspired by childhood to be innovative thinkers, to be ambitious in our ways of caring about the patients and healthcare professionals of tomorrow.

Baliopharm AG, is a biotechnology company focusing on the development of innovative therapeutics for the treatment of chronic liver diseases, immune mediated inflammatory diseases, as well as for cancer.

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) is a commercial-stage biopharmaceutical company headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections.

Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. Our team is driven to make this vision a reality: we are committed to transforming immunological insights into life-changing therapies.

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, including orphan tauopathies, Alzheimer’s and Parkinson’s disease.

Swiss health science co. pioneering clinically proven products to promote cellular health and longevity. The company’s proprietary nutrient, Mitopure, is clinically shown to combat age-related declines in mitochondrial health and muscle function. Nestlé Health Science is a global strategic partner.

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.

Kuhner AG is a leading developer and manufacturer of shaking machines, single use bioreactors, automation systems and online measuring technology for the international market. Furthermore, Kuhner sales lab-equipment (freeze dryers, centrifuges, etc.) to the Swiss market.

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.

AC Immune SA is a clinical-stage biopharma that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and NeuroOrphan indications. The company has two clinically validated technology platforms, SupraAntigen® and Morphomer®.